Scientists at Keio University School of Medicine in Japan published the first study evaluating the safety of human nicotinamide mononucleotide (NMN) administration, showing that there are no adverse health problems. The average life expectancy of humans worldwide has increased, leading to a substantial increase in the number of people suffering from age-related diseases, such as cancer, cardiovascular disease, type 2 diabetes, high blood pressure (hypertension), and macular degeneration. In animal models, the administration of nicotinamide mononucleotide (NMN) has been shown to reduce aging-related dysfunction. However, the effectiveness of NMN in humans, let alone safety, has not been extensively studied.
Clinical trials test NMN in humans
The Keio University School of Medicine research team tested the effects of oral NMN on the human body. To this end, they provided 100, 200 and 500 mg NMN capsules to 10 healthy men. These participants must fast for one night before consuming NMN capsules at 9:00 the next morning. After taking an oral dose of NMN, these people were only allowed to drink water for the next five hours until they received a physical examination. The results showed that participants tolerated NMN well at each dose. They had no gastrointestinal problems or changes in heart rate, blood pressure, oxygen saturation, or body temperature. When Irie and colleagues looked at the nervous system, they could not see any significant changes after taking NMN. The sleep quality of the participants did not change.
Laboratory analysis of blood and urine showed that, except for blood bilirubin, creatinine, chloride, and glucose levels, there was no change before and after taking NMN. Nevertheless, these changes are within the normal range. Evidence from this study shows that a single oral dose of up to 500 mg is safe. “The discovery that oral NMN is feasible, which means that a potential treatment strategy can alleviate aging-related diseases in humans,” Irie and colleagues proposed.